Category Archives: Stem Cell Human Trials

Public release date: 15-Aug-2013 [ | E-mail | Share ] Contact: Katya Nasim katya.nasim@kcl.ac.uk 44-207-848-3840 King's College London Researchers at King's College London have for the first time highlighted the natural regenerative capacity of a group of stem cells that reside in the heart. This new study shows that these cells are responsible for repairing and regenerating muscle tissue damaged by a heart attack which leads to heart failure. The study, published today in the journal Cell, shows that if the stem cells are eliminated, the heart is unable to repair after damage. If the cardiac stem cells are replaced the heart repairs itself, leading to complete cellular, anatomical and functional heart recovery, with the heart returning to normal and pumping at a regular rate. Also, if the cardiac stem cells are removed and re-injected, they naturally 'home' to and repair the damaged heart, a discovery that could lead to less-invasive treatments and even early prevention of heart failure in the future. The study, funded by the European Commission Seventh Framework Programme (FP7), set out to establish the role of cardiac stem cells (eCSCs) by first removing the cells from the hearts of rodents with heart failure. This stopped regeneration … Continue reading →

T cells, colored blue here, move in to attack. In addition to fighting off invaders that arrive from outside the body, the immune system is also able to identify cells that have gone bad inside the body. Even though cancer cells look a lot like normal ones, immune cells can often tell the differenceenough that people who receive long-term treatments of immunosuppressive drugs have a higher incidence of cancer. But the immune system clearly has its limits, or cancer wouldn't be a problem.Cancer cells evolve ways to avoid detection or use the immune system's own signals to tamp down its activity.A number of researchers have been looking for ways to reestablish the immune system's superiority, boosting it in a way that it once again clears out cancer cells. One option for doing so has been to simply boost the cells that already recognize a tumor by isolating them and growing them in large numbers in culture. This doesn't consistently work, however, as it can be hard to identify and isolate tumor-specific immune cells. A team of researchers has figured out a way of taking stem cells, converting them into immune cells, and directing them to attack one type of cancer. … Continue reading →

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2013 and highlighted recent corporate accomplishments. Second Quarter and Recent Corporate Accomplishments We are continuing to make progress towards our goal to become the leader in the field of regenerative medicine. We have the right team in place to capitalize on the opportunities in the field, and we will be one step closer to having the premier asset portfolio in regenerative medicine when our subsidiary Asterias Biotherapeutics, Inc. completes the acquisition of Gerons stem cell assets by the end of the third quarter this year, said Dr. Michael West, BioTimes Chief Executive Officer. We are also making continuing progress in developing our current revenues from Internet services and research product sales as well as in moving our near term diagnostic and therapeutic product opportunities toward clinical trials that are expected to begin later this year. In addition, we continued to raise capital to fund our efforts to provide adequate capital so that we can continue our work in this critical field of medicine. Financial Results Net Loss … Continue reading →

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT;OTCQB: ACTC), a leader in the field of regenerative medicine, announced today second quarter financial results for the period ended June 30, 2013. Highlights of the second quarter include: Second Quarter 2013 Financial Results ACT had revenue totaling $58,268 for the 2013 second quarter, compared to revenue of $218,184 in the prior year. Revenue was generated through license fees and royalty payments. Research and Development expenses for the three months ended June 30, 2013 were $2,862,237, compared to $2,068,098 for same period in 2012. The Company reported a loss from operations of $(5.5) million in the 2013 second quarter compared to a loss from operations of $(4.5) million in the 2012 second quarter. ACT reported a net loss of $(6.6) million or $(0.00) loss per share in the 2013 second quarter, compared to a net loss in the same period of 2012 of $(4.0) million, or $(0.0) per share. Net cash used in operations for the 2013 second quarter was $4.2 million, compared to net cash used in operations of $2.9 million in the same period in 2012. The increase in net cash used in operations was a result of ongoing and additional … Continue reading →

SAN DIEGO, Aug. 6, 2013 (GLOBE NEWSWIRE) -- This year's Stem Cell Action Award honorees, announced today, have funded millions of dollars in stem cell research; raised the standard in medical research journalism; and worked to educate patients, researchers and the entire stem cell community. The 2013 Stem Cell Action Award honorees: Since 2005, Genetics Policy Institute (GPI) has honored the stem cell community's top innovators, leaders, and champions at the Stem Cell Action Awards Dinner at the annual World Stem Cell Summit. The awards will be presented at the 9th Annual Stem Cell Action Awards dinner, Tuesday, December 5, during the 2013 World Stem Cell Summit (WSCS13) at the Manchester Grand Hyatt San Diego, in San Diego, California. "The work done by this year's honorees has directly advanced stem cell research through research, funding and advocacy. They are passionate about making change and we are proud to honor their achievements," said Bernard Siegel, Executive Director of GPI. "These five honorees are sharing knowledge, building infrastructure and supporting the research needed to find cures and alleviate human suffering." Previous Stem Cell Action awardees have included Maryland Governor Martin O'Malley, Research!America, Juvenile Diabetes Research Foundation (JDRF), Michael J. Fox, Robert Klein, … Continue reading →

GAITHERSBURG, MD--(Marketwired - Aug 2, 2013) - Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that it will release financial results for the three- and six-month period ended June 30, 2013, after the close of the market on Wednesday, August 7, 2013. The company will host a conference call beginning at 8:00am Eastern time on Thursday, August 8, 2013 to discuss the second quarter results and to answer questions. Participating in the call will be Martin Rosendale, Chief Executive Officer, and Steven Shallcross, Chief Financial Officer. Conference Call & Webcast Thursday, August 8, 2013 @ 8:00am Eastern/5:00am PacificDomestic dial in: 877-280-4960 International: 857-244-7317 Passcode: 37473493 Webcast: http://www.cytomedix.com Replays - Available through August 15, 2013 Domestic: 888-286-8010 International: 617-801-6888 Passcode: 81192539 About Cytomedix:Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for orthopedics and wound care with a pipeline of adult stem cell therapies for tissue repair. The Company markets the AutoloGel System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds and the Angel Concentrated Platelet Rich Plasma System, a blood processing device and … Continue reading →

NEWARK, Calif., Aug. 2, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today presented data which show that two years after transplantation of the Company's proprietary HuCNS-SC(R) cells (purified human neural stem cells) into patients with Pelizaeus-Merzbacher disease (PMD), the evidence of myelination, by magnetic resonance imaging (MRI), is more pronounced compared to one year post-transplantation, the gains in neurological function reported after one year were maintained, and there were no safety concerns. Patients with PMD have a defective gene which leads to insufficient myelin in the brain, resulting in progressive loss of neurological function and death. The neurological and MRI changes suggest a departure from the natural history of the disease and may represent signals of a clinical effect. The data was presented today by Stephen Huhn, MD, FACS, FAAP, Vice President, CNS Clinical Research at StemCells, Inc., at the 2013 Pelizaeus-Merzbacher Disease Symposium and Health Fair being held at Nemours/Alfred I. duPont Children's Hospital in Wilmington, Del. "We are encouraged that the MRI data continue to indicate new and durable myelination related to the transplanted cells and that the data is even stronger after two years compared to one year," said Dr. Huhn. "Even in the context of a … Continue reading →

Newswise HOUSTON Scientists at The University of Texas MD Anderson who identified a proteins dual role in cancer promotion have discovered a way to shut it down, opening a potential new avenue for cancer treatment. Reporting this week in the journal Cell, the researchers describe the first compound that directly binds to and blocks Skp2, a protein they previously showed both turns off a cellular defense against cancer and switches on a cancer-feeding metabolic pathway. The beauty of this study is we identified an inhibitor and showed how it functions to block Skp2. Inhibitors often are discovered without an initial understanding of how they work, said co-senior author Hui-Kuan Lin, Ph.D., associate professor of Cellular and Molecular Oncology at MD Anderson. Lin teamed with co-senior author Shuxing Zhang, Ph.D., assistant professor of Experimental Therapeutics and head of the Integrated Molecular Discovery Laboratory at MD Anderson, to identify and characterize the drug. There are many more chemical compounds available than there are estimated stars in the universe, Zhang said. We have a database with 10 million compounds, but our prescreening analysis narrowed our computerized search to 120,000 and then further to find small-molecule candidates that inhibit Skp2. Their inhibitor plugs critical … Continue reading →

NEWARK, Calif., July 30, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that it has formally launched its Alzheimer's disease program, which is being supported by the California Institute for Regenerative Medicine (CIRM). The goal of the project is to file, within four years, an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to evaluate the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) as a potential therapeutic in the treatment of Alzheimer's disease. CIRM has agreed to provide approximately $19.3 million to the Company in the form of a forgivable loan to help fund preclinical development and IND-enabling activities, and the Company recently received an initial disbursement of $3.8 million from CIRM. The funding was awarded under CIRM's Disease Team Therapy Development Award program (RFA 10-05) in September 2012. "With CIRM's support, we have taken the first steps towards the development of a novel cell-based therapeutic for use in the treatment of Alzheimer's disease," commented Eliseo Salinas, MD, Executive Vice President and Head of Research & Development at StemCells, Inc. "Today, there are no good treatment options for Alzheimer's disease; in particular, there are no approved drugs which alter the progression of … Continue reading →

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review LiveRoom Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials The Lookout Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Lookout The Sideshow Around the World Katie's Take Power Players This Could Be Big Newsmakers Trending Now Just … Continue reading →